LCM GENECT, an innovative institution in the IVD market, announces the agreement with Autogenomics, a leader company in the automation of molecular diagnostic tests.
With the exclusive licensing, LCM GENECT will provide nationwide the linea INFINITI® plus, a platform based on a patented microarray technology, characterized by high versatility and performance. The platform is an ideal toll for screening and monitoring processes in the contexts of pharmacogenetics, oncology, infectious diseases and genetic disorders.
LCM GENECT together with AutoGenomics will help the Italian laboratories to take a step forward towards Precision Medicine Age.
“INIFINITI® Plus is an instrument that can analyze multiple diseases and different samples at the same time, thereby revolutionizing the approach to the laboratory diagnosis” said Fareed Kureshy, CEO at AutoGenomics, describing the main features of the new platform “and we are sure that a partner as LCM GENECT, a sound company with high scientific reliability, will promote the spread of our technology in the European market”.
“I am fully convinced that the INIFINITI® Plus station is reliable and adaptable to multiple needs: it is the ideal solution to make available the molecular medicine to different kinds of laboratories, both in Italy and in other countries”, claims Riccardo Razzini, Marketing and Sales Manager at LCM GENECT.
LCM Group expresses its satisfaction with the confidence placed by a Partner that is distinguished by technological innovation and dynamism: a new excellent alliance for the start-up Company, with a view to support the growth precision medicine.
